Marinomed Biotech AG/ ATMARINOMED6 /
| - - | Chg. - | Volume | Bid09:06:36 | Ask13:50:09 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 77.50EUR | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | 12.84 mill.EUR | - | - |
Assets
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 2.5000 | 6 | 6.4000 | 6.2000 | 5.9400 | ||||||
| Intangible Assets | 1.6000 | 2.1000 | 2 | 1.8000 | 1.5200 | ||||||
| Long-Term Investments | - | - | - | - | - | ||||||
| Fixed Assets | - | - | - | - | 7.4700 | ||||||
| Inventories | .1000 | .9000 | 1 | 1.6000 | 1.0100 | ||||||
| Accounts Receivable | - | - | - | 4.5200 | 3.5300 | ||||||
| Cash and Cash Equivalents | 12 | 9.2000 | 5.8000 | 8.2000 | 2.5800 | ||||||
| Current Assets | 15.3000 | 15.4000 | 12.9000 | 14.3000 | 7.1300 | ||||||
| Total Assets | 19.5000 | 23.5000 | 21.3000 | 22.3000 | 14.6100 | ||||||
Liabilities
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 1 | 2 | 2 | 1.2000 | 1.5300 | ||||||
| Long-term debt | 4.6000 | 12.5000 | 15.1000 | 20.1800 | 14.8400 | ||||||
| Liabilities to Banks | 4.7000 | 12.9000 | 15.9000 | - | - | ||||||
| Provisions | 1.3000 | .8000 | - | - | - | ||||||
| Liabilities | 8.6000 | 18.1000 | 21.1000 | 26.5000 | 24.7400 | ||||||
| Share Capital | 1.4700 | 1.4730 | 1.4800 | - | - | ||||||
| Total Equity | 10.9000 | 5.4000 | .2000 | -4.1500 | -10.1300 | ||||||
| Minority Interests | - | - | - | 0.0000 | - | ||||||
| Total liabilities equity | 19.5000 | 23.5000 | 21.3000 | 22.3000 | 14.6100 | ||||||
Income Statement
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 6.1000 | 8.1000 | 11.6000 | 11.2700 | 9.1800 | ||||||
| Depreciation (total) | .3000 | .4000 | .6000 | .7000 | .6780 | ||||||
| Operating Result | -6.2000 | -5.8000 | -4.1000 | -4.9100 | -5.1200 | ||||||
| Interest Income | -1 | -.2000 | -1.5000 | -1.5000 | 3.3800 | ||||||
| Income Before Taxes | -7.2000 | -6 | -5.7000 | - | - | ||||||
| Income Taxes | 0.0000 | 0.0000 | .2000 | .0060 | .0040 | ||||||
| Minority Interests Profit | - | - | - | - | 0.0000 | ||||||
| Net Income | -7.2000 | -6 | -5.9000 | -6.4000 | -6.7940 | ||||||
Per Share
Cash Flow
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -7.6000 | -6.9000 | -4.9000 | -5.2000 | -4.5200 | ||||||
| Cash Flow from Investing Activities | -2.4000 | -4 | -.9000 | -.2000 | -.1280 | ||||||
| Cash Flow from Financing | 20.3000 | 8 | 2.4000 | 7.8000 | -.9290 | ||||||
| Decrease / Increase in Cash | 10.3000 | -2.8000 | -3.4000 | - | - | ||||||
| Employees | 35 | 42 | 47 | 49 | 52 | ||||||
